Eupraxia Pharmaceuticals (EPRX) Competitors $5.54 +0.48 (+9.49%) Closing price 03:59 PM EasternExtended Trading$5.67 +0.13 (+2.35%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. CRON, QURE, OCS, ANAB, BGM, CRMD, VIR, KALV, AMLX, and AVBPShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Cronos Group (CRON), uniQure (QURE), Oculis (OCS), AnaptysBio (ANAB), BGM Group (BGM), CorMedix (CRMD), Vir Biotechnology (VIR), KalVista Pharmaceuticals (KALV), Amylyx Pharmaceuticals (AMLX), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Its Competitors Cronos Group uniQure Oculis AnaptysBio BGM Group CorMedix Vir Biotechnology KalVista Pharmaceuticals Amylyx Pharmaceuticals ArriVent BioPharma Cronos Group (NASDAQ:CRON) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability. Does the media favor CRON or EPRX? In the previous week, Eupraxia Pharmaceuticals had 6 more articles in the media than Cronos Group. MarketBeat recorded 7 mentions for Eupraxia Pharmaceuticals and 1 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.00 beat Eupraxia Pharmaceuticals' score of 0.61 indicating that Cronos Group is being referred to more favorably in the media. Company Overall Sentiment Cronos Group Positive Eupraxia Pharmaceuticals Positive Which has preferable valuation & earnings, CRON or EPRX? Cronos Group has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCronos Group$117.61M6.79$41.08M$0.1315.92Eupraxia PharmaceuticalsN/AN/A-$25.50M-$0.76-7.29 Do analysts prefer CRON or EPRX? Eupraxia Pharmaceuticals has a consensus price target of $11.00, suggesting a potential upside of 98.56%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do institutionals and insiders hold more shares of CRON or EPRX? 8.7% of Cronos Group shares are held by institutional investors. 7.3% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, CRON or EPRX? Cronos Group has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Is CRON or EPRX more profitable? Cronos Group has a net margin of 39.69% compared to Eupraxia Pharmaceuticals' net margin of 0.00%. Cronos Group's return on equity of -0.07% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cronos Group39.69% -0.07% -0.07% Eupraxia Pharmaceuticals N/A -367.73%-112.23% SummaryCronos Group beats Eupraxia Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$181.94M$3.06B$5.72B$9.48BDividend YieldN/A2.38%4.59%3.98%P/E Ratio-7.2920.8627.9219.95Price / SalesN/A321.12441.30102.64Price / CashN/A43.2336.5558.97Price / BookN/A8.308.635.90Net Income-$25.50M-$55.19M$3.24B$258.42M7 Day Performance2.40%5.07%3.22%1.94%1 Month Performance27.36%17.61%10.72%12.02%1 Year Performance113.90%7.03%34.94%20.81% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals2.5079 of 5 stars$5.54+9.5%$11.00+98.6%+97.8%$181.94MN/A-7.2929News CoverageAnalyst ForecastGap UpHigh Trading VolumeCRONCronos Group2.4412 of 5 stars$2.02-2.4%N/A-16.1%$798.36M$117.61M15.54450News CoveragePositive NewsQUREuniQure1.8303 of 5 stars$13.96-4.1%$37.82+170.9%+91.4%$796.99M$27.12M-3.18500Upcoming EarningsOCSOculis1.5945 of 5 stars$17.89-1.5%$35.33+97.5%+57.0%$792.91M$780K-6.782ANABAnaptysBio1.4404 of 5 stars$26.63-1.2%$42.38+59.1%-26.9%$791.79M$111.87M-5.49100Analyst ForecastGap UpBGMBGM GroupN/A$8.90+10.1%N/AN/A$785.55M$25.10M0.00298News CoverageGap UpHigh Trading VolumeCRMDCorMedix2.9016 of 5 stars$11.37+0.1%$17.14+50.8%+140.6%$770.49M$43.47M51.6830Positive NewsVIRVir Biotechnology3.6767 of 5 stars$5.30-3.6%$30.25+470.8%-42.6%$760.31M$74.21M-1.26580KALVKalVista Pharmaceuticals4.1095 of 5 stars$15.17-0.3%$26.29+73.3%+1.1%$760.30MN/A-4.11100High Trading VolumeAMLXAmylyx Pharmaceuticals3.2906 of 5 stars$8.12-3.4%$11.75+44.7%+328.1%$749.68M$87.37M-2.61200AVBPArriVent BioPharma2.2966 of 5 stars$21.62-1.1%$39.29+81.7%+7.1%$748.23MN/A-5.7340Positive NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Cronos Group Competitors uniQure Competitors Oculis Competitors AnaptysBio Competitors BGM Group Competitors CorMedix Competitors Vir Biotechnology Competitors KalVista Pharmaceuticals Competitors Amylyx Pharmaceuticals Competitors ArriVent BioPharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EPRX Stock Alerts